Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Takeda’s Shonan Lab Collaborative Research Initiative Forging Ahead
April 27, 2015
- Janssen Files Risperdal for Irritability Associated with Autistic Disorder in Children
April 27, 2015
- Eisai Launches 2 Anticancer Agents in Mexico
April 27, 2015
- Bayer Seeks Japan Approval of Prostate Cancer Drug Radium-223 Dichloride
April 27, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Astellas Sees 59% Rise in FY2014 Operating Profit
April 24, 2015
- Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US
April 24, 2015
- Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”
April 24, 2015
- Astellas Links Up with US Biotech Potenza on Immuno-Oncology
April 23, 2015
- Shionogi Ups FY2014 Earnings Outlook on ViiV Dividends
April 23, 2015
- Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
- Sales Rep Survey - Part 2: Japanese Drug Makers Forging Specialized Forces in Oncology
April 23, 2015
- Daiichi Sankyo Sells All Shares of Sun Pharma
April 22, 2015
- Merck KGaA, Pfizer Start Multinational PIII Study of Anti-PD-L1 Antibody Avelumab
April 22, 2015
- Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
- Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
- Asahi Kasei Pharma Pulls Plug on Liquid Diet Biz
April 21, 2015
- Takeda, Keio, Niigata Univs in Tripartite Research Pact on RNA-Binding Proteins
April 21, 2015
- AbbVie’s Hepatitis C Drug Gets Priority Review in Japan
April 20, 2015
- Nicholas Grund to Come Back as Genzyme Japan President after 8 Months
April 20, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…